nach oben

Current Hypertension Reports

Erschienen in:

01.10.2011

Update on Pathophysiology and Treatment of Hypertension in the Elderly

verfasst von: Debbie L. Cohen, Raymond R. Townsend

Erschienen in: Current Hypertension Reports | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Hypertension is common in the elderly, and its prevalence increases with aging. The vascular system is a prototypical aging tissue, and arterial stiffness plays a major role in hypertension as the individual ages. Some unique aging changes in the nitric oxide and angiotensin II pathways are particularly important for vascular aging. Studies focusing on direct measures of vascular stiffness have increased understanding of the pathophysiology behind increased arterial stiffness. Goal blood pressure in the elderly is debated, but based on current outcome data, a goal blood pressure of 150/80–90 mm Hg is reasonable in at least the very elderly. This review discusses in detail the various landmark hypertension studies in the elderly. We recommend use of thiazide diuretics, long-acting calcium channel blockers, and angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers as either monotherapy or in combination, with beta-blockers reserved for patients with specific indications.

Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D’Agostino RB, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002;287(8):1003–10.PubMedCrossRef

Carlberg B, Nilsson PM. Hypertension in the elderly: what is the goal blood pressure target and how can this be attained? Curr Hypertens Rep. 2010;12(5):331–4.PubMedCrossRef

• Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358(18):1887–98. The HYVET study demonstrates the importance of treating the very elderly patient with hypertension, using a goal BP of 150/80 mm Hg. PubMedCrossRef

• Angeli F, Reboldi G, Verdecchia P. “The lower the BP the better” paradigm in the elderly: vanished by VALISH? Hypertension 2010;56(2):182–4. This is a review of BP goals in the elderly. PubMedCrossRef

JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008;31(12):2115–27.CrossRef

Le Couteur DG, Lakatta EG. A vascular theory of aging. J Gerontol A Biol Sci Med Sci. 2010;65(10):1025–7.PubMedCrossRef

•• Ungvari Z, Kaley G, de Cabo R, Sonntag WE, Csiszar A. Mechanisms of vascular aging: new perspectives. J Gerontol A Biol Sci Med Sci 2010;65(10):1028–41. This is an excellent review of mechanisms of vascular aging. PubMedCrossRef

Wang M, Zhang J, Spinetti G, et al. Angiotensin II activates matrix metalloproteinase type II and mimics age-associated carotid arterial remodeling in young rats. Am J Pathol. 2005;167:1429–42.PubMedCrossRef

Rudner XL, Berkowitz DE, Booth JV, Funk BL, Cozart KL, D’Amico EB, et al. Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age. Circulation. 1999;100(23):2336–43.PubMed

10.

Michel JB, Heudes D, Michel O, Poitevin P, Philippe M, Scalbert E, et al. Effect of chronic ANG I-converting enzyme inhibition on aging processes. II. Large arteries. Am J Physiol. 1994;267(1 Pt 2):R124–35.PubMed

11.

Basso N, Cini R, Pietrelli A, Ferder L, Terragno NA, Inserra F. Protective effect of long-term angiotensin II inhibition. Am J Physiol Heart Circ Physiol. 2007;293(3):H1351–8.PubMedCrossRef

12.

Sarzani R, Arnaldi G, Takasaki I, Brecher P, Chobanian AV. Effects of hypertension and aging on platelet-derived growth factor and platelet-derived growth factor receptor expression in rat aorta and heart. Hypertension. 1991;18(5 Suppl):III93–9.PubMed

13.

Wu R, Millette E, Wu L, de Champlain J. Enhanced superoxide anion formation in vascular tissues from spontaneously hypertensive and desoxycorticosterone acetate-salt hypertensive rats. J Hypertens. 2001;19(4):741–8.PubMedCrossRef

14.

Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, et al. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest. 2009;119(3):524–30.PubMedCrossRef

15.

Linz W, Heitsch H, Scholkens BA, Wiemer G. Long-term angiotensin II type 1 receptor blockade with fonsartan doubles lifespan of hypertensive rats. Hypertension. 2000;35(4):908–13.PubMed

16.

Wang M, Monticone RE, Lakatta EG. Arterial aging: a journey into subclinical arterial disease. Curr Opin Nephrol Hypertens. 2010;19(2):201–7.PubMedCrossRef

17.

Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444(7117):337–42.PubMedCrossRef

18.

Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, Labinskyy N, et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008;8(2):157–68.PubMedCrossRef

19.

O’Rourke MF. Arterial aging: pathophysiological principles. Vasc Med. 2007;12(4):329–41.PubMedCrossRef

20.

Virmani R, Avolio AP, Mergner WJ, Robinowitz M, Herderick EE, Cornhill JF, et al. Effect of aging on aortic morphology in populations with high and low prevalence of hypertension and atherosclerosis. Comparison between occidental and Chinese communities. Am J Pathol. 1991;139(5):1119–29.PubMed

21.

Nagai Y, Metter EJ, Earley CJ, Kemper MK, Becker LC, Lakatta EG, et al. Increased carotid artery intimal-medial thickness in asymptomatic older subjects with exercise-induced myocardial ischemia. Circulation. 1998;98(15):1504–9.PubMed

22.

Gerhard M, Roddy MA, Creager SJ, Creager MA. Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans. Hypertension. 1996;27(4):849–53.PubMed

23.

Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol. 1994;24(6):1468–74.PubMedCrossRef

24.

• DeLoach SS, Townsend RR. Vascular stiffness: its measurement and significance for epidemiologic and outcome studies. Clin J Am Soc Nephrol 2008;3(1):184–92. This article reviews vascular stiffness and its significance. PubMedCrossRef

25.

Mitchell GF, Parise H, Benjamin EJ, Larson MG, Keyes MJ, Vita JA, et al. Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. Hypertension. 2004;43(6):1239–45.PubMedCrossRef

26.

Reference Values for Arterial Stiffness’ Collaboration: Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’. Eur Heart J 2010;31(19):2338–50.

27.

Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27(21):2588–605.PubMedCrossRef

28.

Laurent S, Caviezel B, Beck L, Girerd X, Billaud E, Boutouyrie P, et al. Carotid artery distensibility and distending pressure in hypertensive humans. Hypertension. 1994;23(6 Pt 2):878–83.PubMed

29.

O’Rourke MF, Hashimoto J. Mechanical factors in arterial aging: a clinical perspective. J Am Coll Cardiol. 2007;50(1):1–13.PubMedCrossRef

30.

Mitchell GF. Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage. J Appl Physiol. 2008;105(5):1652–60.PubMedCrossRef

31.

Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27(11):2121–58.PubMedCrossRef

32.

• Grassi G, Quarti-Trevano F, Dell’Oro R, Mancia G. The “J curve” problem revisited: old and new findings. Curr Hypertens Rep 2010;12(4):290–5. This is a helpful review of the J-curve phenomenon. PubMedCrossRef

33.

Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet. 1987;1(8533):581–4.PubMedCrossRef

34.

Stewart IM. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet. 1979;1(8121):861–5.PubMedCrossRef

35.

Untreated mild hypertension. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Lancet 1982;1(8265):185–91.

36.

Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group. J Hypertens 1985;3(4):379–92.

37.

Lindholm L, Lanke J, Bengtsson B, Ejlertsson G, Thulin T, Schersten B. Both high and low blood pressures risk indicators of death in middle-aged males. Isotonic regression of blood pressure on age applied to data from a 13-year prospective study. Acta Med Scand. 1985;218(5):473–80.PubMedCrossRef

38.

D’Agostino RB, Belanger AJ, Kannel WB, Cruickshank JM. Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: the Framingham Study. BMJ. 1991;303(6799):385–9.PubMedCrossRef

39.

Voko Z, Bots ML, Hofman A, Koudstaal PJ, Witteman JC, Breteler MM. J-shaped relation between blood pressure and stroke in treated hypertensives. Hypertension. 1999;34(6):1181–5.PubMed

40.

Boutitie F, Gueyffier F, Pocock S, Fagard R, Boissel JP. J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data. Ann Intern Med. 2002;136(6):438–48.PubMed

41.

Mancia G, Messerli F, Bakris G, Zhou Q, Champion A, Pepine CJ. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension. 2007;50(2):299–305.PubMedCrossRef

42.

Fagard RH, Staessen JA, Thijs L, Celis H, Bulpitt CJ, de Leeuw PW, et al. On-treatment diastolic blood pressure and prognosis in systolic hypertension. Arch Intern Med. 2007;167(17):1884–91.PubMedCrossRef

43.

Denardo SJ, Gong Y, Nichols WW, Messerli FH, Bavry AA, Cooper-Dehoff RM, et al. Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. Am J Med. 2010;123(8):719–26.PubMedCrossRef

44.

Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, et al. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J. 2010;31(23):2897–908.PubMedCrossRef

45.

Amery A, Birkenhager W, Brixko P, Bulpitt C, Clement D, Deruyttere M, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985;1(8442):1349–54.PubMedCrossRef

46.

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991;265(24):3255–64.

47.

Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338(8778):1281–5.PubMedCrossRef

48.

Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 1992;304(6824):405–12.

49.

Gueyffier F, Bulpitt C, Boissel JP, Schron E, Ekbom T, Fagard R, et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet. 1999;353(9155):793–6.PubMedCrossRef

50.

Oates DJ, Berlowitz DR, Glickman ME, Silliman RA, Borzecki AM. Blood pressure and survival in the oldest old. J Am Geriatr Soc. 2007;55(3):383–8.PubMedCrossRef

51.

Staessen J. Mortality and treated blood pressure in patients of the European Working Party on High Blood Pressure in the Elderly. Am J Med 1991;90(3A):60S–61S.

52.

Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350(9080):757–64.PubMedCrossRef

53.

Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998;16(12 Pt 1):1823–9.

54.

• Jissho S, Shimada K, Taguchi H, Yoshida K, Fukuda S, Tanaka H, et al. Impact of electrocardiographic left ventricular hypertrophy on the occurrence of cardiovascular events in elderly hypertensive patients—The Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Circ J 2010;74(5):938–45. The JATOS study does not demonstrate benefit for treating to a lower goal BP in the elderly. PubMedCrossRef

55.

• Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension 2010;56(2):196–202. The VALISH study does not demonstrate benefit from treating to a lower goal BP in the elderly. PubMedCrossRef

56.

Wilkinson IB, Franklin SS, Hall IR, Tyrrell S, Cockcroft JR. Pressure amplification explains why pulse pressure is unrelated to risk in young subjects. Hypertension. 2001;38(6):1461–6.PubMedCrossRef

Titel: Update on Pathophysiology and Treatment of Hypertension in the Elderly
verfasst von: Debbie L. Cohen
Raymond R. Townsend
Publikationsdatum: 01.10.2011
Verlag: Current Science Inc.
Erschienen in: Current Hypertension Reports / Ausgabe 5/2011
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-011-0215-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Update on Pathophysiology and Treatment of Hypertension in the Elderly

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2011

Resistant Hypertension: Concepts and Approach to Management

Blood Oxygen Level–Dependent (BOLD) MRI in Renovascular Hypertension

Systolic Blood Pressure and Mortality in Patients on Hemodialysis

Improving Genetic Testing for Gitelman’s Syndrome

Is Nocturnal Blood Pressure Reduction the Secret to Reducing the Rate of Progression of Hypertensive Chronic Kidney Disease?

Hydrochlorothiazide Versus Calcium Channel Blockers: What is the Best Add-on to a Renin-Angiotensin System Blocker for Treating Hypertension in Patients with Renal Disease?

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin